No abstract is available for this article. mehr
Um alle Funktionen dieser Seite zu nutzen, aktivieren Sie bitte die Cookies in Ihrem Browser.
Mit einem my.bionity.com-Account haben Sie immer alles im Überblick - und können sich Ihre eigene Website und Ihren individuellen Newsletter konfigurieren.
We compared the pharmacokinetic (PK) profiles of Co‐Crystal of Tramadol‐Celecoxib (CTC) versus each reference product (alone and in open combination) after single (first dose) and multiple dosing.Methods
Healthy adults aged 18–50 years received, under fasted conditions, 15 twice‐daily doses of the following treatments (separated by ≥14‐day wash‐out): 200 mg immediate‐release (IR) CTC (equivalent to 88 mg tramadol and 112 mg celecoxib; Treatment‐1); 100 mg IR tramadol (Treatment‐2), 100 mg celecoxib (Treatment‐3); and 100 mg IR tramadol and 100 mg celecoxib (Treatment‐4). Treatment sequence was assigned by computer‐generated randomization. PK parameters were calculated using non‐compartmental analysis. Parameters for CTC were adjusted according to reference product dose.Results
Thirty subjects (20 males, mean age 35 years) were included. Multiple‐dose tramadol PK parameters for Treatments‐1, ‐2 and ‐4, respectively, were 551, 632 and 661 ng ml‐1 (mean maximum plasma concentration [Cmax]); 4796, 4990 and 5284 ng h ml‐1 (area under the plasma concentration–time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state). For Treatments‐1, ‐3 and ‐4, multiple‐dose celecoxib PK parameters were 445, 536 and 396 ng ml‐1; 2803, 3366 and 2897 ng h ml‐1; and 2.0, 2.0 and 3.0 h. Single‐dose findings were consistent with multiple‐dose data. Types of adverse events were consistent with known reference product safety profiles.Conclusion
After single (first dose) and multiple dosing, PK parameters of each active pharmaceutical ingredient in CTC were modified by co‐crystallization compared with reference products alone or in open combination.
|Autoren:||Sebastián Videla, Mounia Lahjou, Anna Vaqué, Mariano Sust, Marisol Escriche, Lluis Soler, Artur Sans, Eric Sicard, Neus Gascón, Gregorio Encina, Carlos Plata‐Salamán|
|Journal:||British Journal of Clinical Pharmacology|
Abstract The single radial immunodiffusion assay has been the accepted method for determining the potency of inactivated influenza vaccines since 1978. The world‐wide adoption of this assay for vaccine standardisation was facilitated through collaborative studies that demonstrated a high ... mehr
Abstract Background Whether morbidity from the 1918‐19 influenza pandemic discriminated by socioeconomic status has remained a subject of debate for 100 years. In lack of data to study this issue recent literature have hypothesized that morbidity was “socially neutral”. Objectives ... mehr